minoxidil has been researched along with verapamil in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (27.27) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 11 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Cuddon, P; Fleming, A; Floto, RA; Goldsmith, P; Jahreiss, L; O'Kane, CJ; Pask, D; Rubinsztein, DC; Saiki, S; Sarkar, S; Siddiqi, FH; Ttofi, EK; Williams, A | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Conradi, R; Lee, PH; Shanmugasundaram, V | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Littler, WA; Smith, SA | 1 |
| Ruskoaho, HJ; Savolainen, ER | 1 |
| Nast, HP; Philipp, T | 1 |
| Anand, MP | 1 |
| Kochar, MS | 1 |
| Bar-Andziak, E; Chlewicka, I | 1 |
| Elliott, WJ | 1 |
| Elias, PM; Feingold, KR; Lee, SH; Mauro, T | 1 |
| Chang, Y; Fu, J; Gu, X; Han, DY; Ji, HL; Nayak, RC; Nie, HG; Rao, V; Su, XF | 1 |
| Hosek, P; Hoskova, K; Nevoral, J; Petelak, A; Petr, J; Stiavnicka, M; Zalmanova, T | 1 |
3 review(s) available for minoxidil and verapamil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antihypertensive agents--the race for third place.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Captopril; Diazoxide; Felodipine; Humans; Hydralazine; Indoramin; Labetalol; Minoxidil; Nicardipine; Nifedipine; Vasodilator Agents; Verapamil | 1985 |
Hypertension--drug management.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Captopril; Diazoxide; Humans; Hypertension; Indoramin; Labetalol; Minoxidil; Nifedipine; Nitroprusside; Prazosin; Sympatholytics; Vasodilator Agents; Verapamil | 1982 |
19 other study(ies) available for minoxidil and verapamil
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
Topics: Animals; Autophagy; Calcium Channels, L-Type; Clonidine; Cyclic AMP; Humans; Huntington Disease; Imidazoline Receptors; Minoxidil; Protein Kinases; Signal Transduction; TOR Serine-Threonine Kinases; Type C Phospholipases; Verapamil | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
Topics: 1-Methyl-3-isobutylxanthine; Cell Line; Cell Membrane Permeability; Humans; Models, Biological; Quantitative Structure-Activity Relationship; Skin Absorption | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects of long-term verapamil treatment on blood pressure, cardiac hypertrophy and collagen metabolism in spontaneously hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Cardiomegaly; Collagen; Female; Heart; Hydroxyproline; Hypertension; Male; Minoxidil; Myocardium; Pregnancy; Procollagen-Proline Dioxygenase; Rats; Rats, Inbred SHR; Time Factors; Verapamil | 1985 |
[Hypertensive emergencies].
Topics: Brain Edema; Clonidine; Diazoxide; Digitalis Glycosides; Diuretics; Drug Combinations; Emergencies; Ferricyanides; Ganglionic Blockers; Guanethidine; Humans; Hydralazine; Hypertension; Hypertension, Malignant; Hypnotics and Sedatives; Intensive Care Units; Methyldopa; Minoxidil; Nitric Oxide; Pheochromocytoma; Reserpine; Verapamil | 1974 |
Simultaneous treatment of Raynaud's phenomenon and orthostatic hypotension.
Topics: Drug Therapy, Combination; Ephedrine; Female; Fludrocortisone; Follow-Up Studies; Humans; Hydralazine; Hypotension, Orthostatic; Methylphenidate; Middle Aged; Minoxidil; Raynaud Disease; Sympathectomy; Verapamil | 1983 |
[New hypotensive drugs].
Topics: Antihypertensive Agents; Captopril; Drug Evaluation; Guanfacine; Guanidines; Humans; Hypertension; Labetalol; Minoxidil; Nifedipine; Phenylacetates; Saralasin; Verapamil | 1981 |
An individualized approach to the hypertensive patient with renal disease: six illustrative case studies.
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arterial Occlusive Diseases; Auscultation; Benzothiadiazines; Cough; Diabetes Mellitus, Type 1; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Hypertension; Male; Middle Aged; Minoxidil; Prazosin; Proteinuria; Sodium Chloride Symporter Inhibitors; Verapamil | 1995 |
A role for ions in barrier recovery after acute perturbation.
Topics: Animals; Calcium; Calcium Channels; Calmodulin; Cell Membrane Permeability; Diazoxide; Dihydropyridines; Homeostasis; Ions; Mice; Mice, Hairless; Minoxidil; Ouabain; Permeability; Potassium; Potassium Channels; Skin; Skin Physiological Phenomena; Sodium-Potassium-Exchanging ATPase; Verapamil; Water-Electrolyte Balance | 1994 |
K+ channel openers restore verapamil-inhibited lung fluid resolution and transepithelial ion transport.
Topics: Animals; Benzimidazoles; Calcium; Calcium Channel Blockers; Calcium Signaling; Dose-Response Relationship, Drug; Epithelial Cells; Epithelial Sodium Channels; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; KATP Channels; Lung; Male; Membrane Potentials; Mice; Mice, Inbred C57BL; Minoxidil; Potassium; Potassium Channels; Pulmonary Edema; Pyridines; Sodium; Thiones; Verapamil; Xenopus laevis | 2010 |
Involvement of K
Topics: Adenosine Triphosphate; Animals; Calcium Channel Blockers; Calcium Channels; Cellular Senescence; Female; Hydrogen Sulfide; Minoxidil; Oocytes; Phenotype; Potassium Channels, Calcium-Activated; Signal Transduction; Swine; Verapamil | 2018 |